Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21200967 | 0.87 | MEN1 (0.35) | CYP2C19MEN1KMT2A | |
| SCHEMBL29866714 | 0.83 | HCRTR1 (0.44) | HCRTR1HCRTR2RXFP1RORCBRD4 | |
| SCHEMBL28940818 | 0.78 | RXFP1 (0.45) | HCRTR1HCRTR2RXFP1RORCBRD4 | |
| SCHEMBL29626649 | 0.78 | RXFP1 (0.45) | HCRTR1HCRTR2RXFP1RORCBRD4 | |
| SCHEMBL29866952 | 0.75 | HCRTR1 (0.46) | HCRTR1HCRTR2RXFP1RORCBRD4 | |
| SCHEMBL30903034 | 0.75 | CBLB (0.46) | HCRTR1HCRTR2BRD4CYP17A1PRMT5 | |
| SCHEMBL27273953 | 0.75 | HCRTR1 (0.45) | HCRTR1HCRTR2BRD4CREBBPCYP17A1 | |
| SCHEMBL21200853 | 0.74 | HCRTR1 (0.45) | HCRTR1HCRTR2RXFP1RORCBRD4 | |
| SCHEMBL24818834 | 0.72 | CBLB (0.49) | HCRTR1HCRTR2RORC | |
| SCHEMBL29535994 | 0.72 | CBLB (0.49) | HCRTR1HCRTR2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | HCRTR1 4150/4885HCRTR2 4393/4885RXFP1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.